Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.
Identifieur interne : 000116 ( Main/Exploration ); précédent : 000115; suivant : 000117Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.
Auteurs : Marcel Kaiser [Suisse] ; Louis Maes [Belgique] ; Leela Pavan Tadoori [Suisse] ; Thomas Spangenberg [Suisse] ; Jean-Robert IosetSource :
- Journal of biomolecular screening [ 1552-454X ] ; 2015.
English descriptors
- KwdEn :
- Animals, Antimalarials (pharmacology), Cell Line, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Discovery (methods), Drug Repositioning, Inhibitory Concentration 50, Male, Mice, Parasitic Sensitivity Tests (methods), Small Molecule Libraries, Trypanocidal Agents (pharmacology), Trypanosomatina (drug effects).
- MESH :
- chemical , pharmacology : Antimalarials, Trypanocidal Agents.
- drug effects : Trypanosomatina.
- methods : Drug Discovery, Parasitic Sensitivity Tests.
- Animals, Cell Line, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Repositioning, Inhibitory Concentration 50, Male, Mice, Small Molecule Libraries.
Abstract
Phenotypic screening had successfully been used for hit generation, especially in the field of neglected diseases, in which feeding the drug pipeline with new chemotypes remains a constant challenge. Here, we catalyze drug discovery research using a publicly available screening tool to boost drug discovery. The Malaria Box, assembled by the Medicines for Malaria Venture, is a structurally diverse set of 200 druglike and 200 probelike compounds distilled from more than 20,000 antimalarial hits from corporate and academic libraries. Repurposing such compounds has already identified new scaffolds against cryptosporidiosis and schistosomiasis. In addition to initiating new hit-to-lead activities, screening the Malaria Box against a plethora of other parasites would enable the community to better understand the similarities and differences between them. We describe the screening of the Malaria Box and triaging of the identified hits against kinetoplastids responsible for human African trypanosomiasis (Trypanosoma brucei), Chagas disease (Trypanosoma cruzi), and visceral leishmaniasis (Leishmania donovani and Leishmania infantum). The in vitro and in vivo profiling of the most promising active compounds with respect to efficacy, toxicity, pharmacokinetics, and complementary druggable properties are presented and a collaborative model used as a way to accelerate the discovery process discussed.
DOI: 10.1177/1087057115569155
PubMed: 25690568
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000033
- to stream PubMed, to step Curation: 000033
- to stream PubMed, to step Checkpoint: 000033
- to stream Ncbi, to step Merge: 000290
- to stream Ncbi, to step Curation: 000290
- to stream Ncbi, to step Checkpoint: 000290
- to stream Main, to step Merge: 000116
- to stream Main, to step Curation: 000116
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.</title><author><name sortKey="Kaiser, Marcel" sort="Kaiser, Marcel" uniqKey="Kaiser M" first="Marcel" last="Kaiser">Marcel Kaiser</name><affiliation wicri:level="1"><nlm:affiliation>Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Maes, Louis" sort="Maes, Louis" uniqKey="Maes L" first="Louis" last="Maes">Louis Maes</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Tadoori, Leela Pavan" sort="Tadoori, Leela Pavan" uniqKey="Tadoori L" first="Leela Pavan" last="Tadoori">Leela Pavan Tadoori</name><affiliation wicri:level="1"><nlm:affiliation>Drugs for Neglected Diseases initiative, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Drugs for Neglected Diseases initiative, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Spangenberg, Thomas" sort="Spangenberg, Thomas" uniqKey="Spangenberg T" first="Thomas" last="Spangenberg">Thomas Spangenberg</name><affiliation wicri:level="1"><nlm:affiliation>Medicines for Malaria Venture, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Medicines for Malaria Venture, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Ioset, Jean Robert" sort="Ioset, Jean Robert" uniqKey="Ioset J" first="Jean-Robert" last="Ioset">Jean-Robert Ioset</name><affiliation><nlm:affiliation>Drugs for Neglected Diseases initiative, Geneva, Switzerland jrioset@dndi.org.</nlm:affiliation><wicri:noCountry code="subField">Switzerland jrioset@dndi.org.</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25690568</idno><idno type="pmid">25690568</idno><idno type="doi">10.1177/1087057115569155</idno><idno type="wicri:Area/PubMed/Corpus">000033</idno><idno type="wicri:Area/PubMed/Curation">000033</idno><idno type="wicri:Area/PubMed/Checkpoint">000033</idno><idno type="wicri:Area/Ncbi/Merge">000290</idno><idno type="wicri:Area/Ncbi/Curation">000290</idno><idno type="wicri:Area/Ncbi/Checkpoint">000290</idno><idno type="wicri:Area/Main/Merge">000116</idno><idno type="wicri:Area/Main/Curation">000116</idno><idno type="wicri:Area/Main/Exploration">000116</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.</title><author><name sortKey="Kaiser, Marcel" sort="Kaiser, Marcel" uniqKey="Kaiser M" first="Marcel" last="Kaiser">Marcel Kaiser</name><affiliation wicri:level="1"><nlm:affiliation>Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Maes, Louis" sort="Maes, Louis" uniqKey="Maes L" first="Louis" last="Maes">Louis Maes</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratory of Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Tadoori, Leela Pavan" sort="Tadoori, Leela Pavan" uniqKey="Tadoori L" first="Leela Pavan" last="Tadoori">Leela Pavan Tadoori</name><affiliation wicri:level="1"><nlm:affiliation>Drugs for Neglected Diseases initiative, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Drugs for Neglected Diseases initiative, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Spangenberg, Thomas" sort="Spangenberg, Thomas" uniqKey="Spangenberg T" first="Thomas" last="Spangenberg">Thomas Spangenberg</name><affiliation wicri:level="1"><nlm:affiliation>Medicines for Malaria Venture, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Medicines for Malaria Venture, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Ioset, Jean Robert" sort="Ioset, Jean Robert" uniqKey="Ioset J" first="Jean-Robert" last="Ioset">Jean-Robert Ioset</name><affiliation><nlm:affiliation>Drugs for Neglected Diseases initiative, Geneva, Switzerland jrioset@dndi.org.</nlm:affiliation><wicri:noCountry code="subField">Switzerland jrioset@dndi.org.</wicri:noCountry></affiliation></author></analytic><series><title level="j">Journal of biomolecular screening</title><idno type="eISSN">1552-454X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antimalarials (pharmacology)</term><term>Cell Line</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Discovery (methods)</term><term>Drug Repositioning</term><term>Inhibitory Concentration 50</term><term>Male</term><term>Mice</term><term>Parasitic Sensitivity Tests (methods)</term><term>Small Molecule Libraries</term><term>Trypanocidal Agents (pharmacology)</term><term>Trypanosomatina (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antimalarials</term><term>Trypanocidal Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Trypanosomatina</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term><term>Parasitic Sensitivity Tests</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Repositioning</term><term>Inhibitory Concentration 50</term><term>Male</term><term>Mice</term><term>Small Molecule Libraries</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Phenotypic screening had successfully been used for hit generation, especially in the field of neglected diseases, in which feeding the drug pipeline with new chemotypes remains a constant challenge. Here, we catalyze drug discovery research using a publicly available screening tool to boost drug discovery. The Malaria Box, assembled by the Medicines for Malaria Venture, is a structurally diverse set of 200 druglike and 200 probelike compounds distilled from more than 20,000 antimalarial hits from corporate and academic libraries. Repurposing such compounds has already identified new scaffolds against cryptosporidiosis and schistosomiasis. In addition to initiating new hit-to-lead activities, screening the Malaria Box against a plethora of other parasites would enable the community to better understand the similarities and differences between them. We describe the screening of the Malaria Box and triaging of the identified hits against kinetoplastids responsible for human African trypanosomiasis (Trypanosoma brucei), Chagas disease (Trypanosoma cruzi), and visceral leishmaniasis (Leishmania donovani and Leishmania infantum). The in vitro and in vivo profiling of the most promising active compounds with respect to efficacy, toxicity, pharmacokinetics, and complementary druggable properties are presented and a collaborative model used as a way to accelerate the discovery process discussed.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>Suisse</li></country></list><tree><noCountry><name sortKey="Ioset, Jean Robert" sort="Ioset, Jean Robert" uniqKey="Ioset J" first="Jean-Robert" last="Ioset">Jean-Robert Ioset</name></noCountry><country name="Suisse"><noRegion><name sortKey="Kaiser, Marcel" sort="Kaiser, Marcel" uniqKey="Kaiser M" first="Marcel" last="Kaiser">Marcel Kaiser</name></noRegion><name sortKey="Spangenberg, Thomas" sort="Spangenberg, Thomas" uniqKey="Spangenberg T" first="Thomas" last="Spangenberg">Thomas Spangenberg</name><name sortKey="Tadoori, Leela Pavan" sort="Tadoori, Leela Pavan" uniqKey="Tadoori L" first="Leela Pavan" last="Tadoori">Leela Pavan Tadoori</name></country><country name="Belgique"><noRegion><name sortKey="Maes, Louis" sort="Maes, Louis" uniqKey="Maes L" first="Louis" last="Maes">Louis Maes</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000116 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000116 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25690568
|texte= Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25690568" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a OpenAccessBelV2
| This area was generated with Dilib version V0.6.25. |  |